Can a Bitcoin ETF 30x Your Money?
If you’re bullish on Bitcoin but want more than just price appreciation, the MSTY ETF might be the most interesting option on the table.
MSTY (YieldMax MSTR Option Income Strategy ETF) is a covered call fund on MicroStrategy, a company whose stock is effectively a leveraged bet on Bitcoin.
Since launching in 2024,
» Read more about: Can a Bitcoin ETF 30x Your Money? »
Read More
The Horrifying Chart That May Forecast A Plunge
Technical charts are littered with examples of historical comparisons. Is the most recent bullish run-up in the S&P 500 similar to the 1929 peak? Is the hype around AI similar to the buzz around the internet in 2000? Is the soaring Nvidia stock chart akin to the bull run in Cisco 24 years ago?
It’s hard to tell looking at a stock chart alone whether history will repeat or simply rhyme,
» Read more about: The Horrifying Chart That May Forecast A Plunge »
Read More
1 Healthcare Firm Billion Dollar Funds Bets On
Lantheus Holdings isn’t a healthcare firm that springs to the top of investors’ minds as say a United Healthcare might but it’s attracted the interest of one money manager who oversees almost $20 billion, Farallon Capital Management.
What is it that this astute asset manager sees in this off-the-radar firm which has sold off big time in the past 3 months?
» Read more about: 1 Healthcare Firm Billion Dollar Funds Bets On »
Read More
The Best Stock Over The Past 25 Years
You would probably assume that Apple’s rise to become a $3 trillion market capitalization company cements its holding on the title of the best performing stock over the past quarter century. If not Steve Jobs’s firm, surely Microsoft holds the top spot as the largest company by valuation in the S&P 500 today?
It turns out neither company has the title,
» Read more about: The Best Stock Over The Past 25 Years »
Read More
This High-Yield Fidelity ETF Is Beating the Market, Here’s Why
Fidelity’s High Dividend ETF (FDVV) is a fund that offers a compelling combination of both current dividend income and growth potential. The fund began in September of 2016 and has delivered a 12.8% lifetime annualized return as well as a steady stream of dividends to its shareholders.
Is the Fidelity High Dividend ETF a good investment to make today,
» Read more about: This High-Yield Fidelity ETF Is Beating the Market, Here’s Why »
Read MoreThe Burst
Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year,
» Read more about: Massive Upside In Big Money Pharma Favorite? »
Read MoreThe Spotlight
Spotlight: Market Crash Incoming?
Some stock market indicators are better than others but have you heard of one being perfect for over a century? If the cyclically adjusted price-to-earnings ratio, better known as CAPE, is to be believed, then the markets could be set for a rocky road this year.
Unlike traditional PE ratios, the CAPE figure factors in inflation and smooths the peaks and troughs of unforeseen or surprising events –
» Read more about: Spotlight: Market Crash Incoming? »
Read MoreThe Daily
Cell C set to pay dividends after listing
<!–>
Listing Cell C will allow Blu Label Unlimited to clear debt.
]–>
Cell C is set to pay its first-ever dividend at the end of its 2027 financial year,
» Read more about: Cell C set to pay dividends after listing »